Form 4 for CLDX Celldex Therapeutics, Inc.
Accepted 2021-12-10 00:00:00 ET · period of report 2021-12-08 · accession 0001179110-21-010819 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-10 | 2021-12-08 | CLDX | Crowley Elizabeth | SVP, CPDO | M - OptEx | $9.02 | +4,000 | 8,726 | +85% | +$36.1K |
| D | 2021-12-10 | 2021-12-08 | CLDX | Crowley Elizabeth | SVP, CPDO | S - Sale+OE | $40.00 | -4,000 | 4,726 | -46% | -$160.0K |
| D | 2021-12-10 | 2021-12-08 | CLDX | Crowley Elizabeth | SVP, CPDO | M - OptEx | $0.00 | -4,000 | 16.0K | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-08 | M | A | 4,000 | $9.02 | 8,726 | D | — | — | (F1) On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. |
| 2 | Common | Common Stock | 2021-12-08 | S | D | 4,000 | $40.00 | 4,726 | D | — | — | (F2) The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021. |
| 3 | Derivative | Incentive Stock Option (Right to Buy) | 2021-12-08 | M | D | 4,000 | $0.00 | 16,000 | D | $9.02 · — to 2028-06-13 | 4,000 Common Stock | (F1) On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. (F3) 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |